טוען...
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
BACKGROUND: Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been extensively studied, however, not much is known about the involvement of microR...
שמור ב:
| הוצא לאור ב: | Mol Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4650519/ https://ncbi.nlm.nih.gov/pubmed/26576679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0464-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|